India Covid Vaccine Covaxin
- All
- News
- Videos
-
Top Medical Body Slams Study On Covaxin Safety, Side-Effects, Wants Apology
The Indian Council of Medical Research, or ICMR, has distanced itself from a follow-up study by two Banaras Hindu University professors that said nearly a third of 926 individuals who got the India-made Covaxin shot reported serious side-effects.
-
Fact Check: Can Covaxin Lead To Death After 2 Years Of Vaccination?
As per a social media user, Covaxin COVID vaccine can cause death after two years of vaccination. The user also claims that the Covaxin has caused the deaths of crores of people. We did the fact check and it came out to be false.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
Covaxin Maker Gets $19 Million For Development Of 'Variant Proof' Vaccine
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.
-
"Portrays Incorrect Picture": Government On Reports Of Covaxin Concern
Centre said that reports apparently quoting a communication from the MEA asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval nod for its COVID jab, "potrayed an incorrect picture."
-
Covaxin, Covishield Recipients Had Same Infection Rate In 3rd Wave: Study
Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.
-
Covid Booster Shots Off To A Slow Start In Delhi
Administering of precaution dose of COVID-19 vaccines began in Delhi on Sunday amid a steady rise in daily case count in the last few days here, even as the pace was sluggish with a few private vaccination centres starting the exercise.
-
Private Hospitals In Delhi, Tamil Nadu Yet To Slash Covid Vaccine Prices
Private hospitals in Tamil Nadu have not slashed the prices of Covid vaccines -- Covishield ad Covaxin -- even though the government has announced a massive reduction.
-
Top Medical Body Slams Study On Covaxin Safety, Side-Effects, Wants Apology
The Indian Council of Medical Research, or ICMR, has distanced itself from a follow-up study by two Banaras Hindu University professors that said nearly a third of 926 individuals who got the India-made Covaxin shot reported serious side-effects.
-
Fact Check: Can Covaxin Lead To Death After 2 Years Of Vaccination?
As per a social media user, Covaxin COVID vaccine can cause death after two years of vaccination. The user also claims that the Covaxin has caused the deaths of crores of people. We did the fact check and it came out to be false.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
Covaxin Maker Gets $19 Million For Development Of 'Variant Proof' Vaccine
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.
-
"Portrays Incorrect Picture": Government On Reports Of Covaxin Concern
Centre said that reports apparently quoting a communication from the MEA asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval nod for its COVID jab, "potrayed an incorrect picture."
-
Covaxin, Covishield Recipients Had Same Infection Rate In 3rd Wave: Study
Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.
-
Covid Booster Shots Off To A Slow Start In Delhi
Administering of precaution dose of COVID-19 vaccines began in Delhi on Sunday amid a steady rise in daily case count in the last few days here, even as the pace was sluggish with a few private vaccination centres starting the exercise.
-
Private Hospitals In Delhi, Tamil Nadu Yet To Slash Covid Vaccine Prices
Private hospitals in Tamil Nadu have not slashed the prices of Covid vaccines -- Covishield ad Covaxin -- even though the government has announced a massive reduction.
